Shares of Quantum BioPharma Ltd. (NASDAQ: QNTM) surged 95% after the company announced positive clinical trial results for its dietary supplement unbuzzd™. The trial demonstrated that unbuzzd™ accelerates alcohol metabolism, leading to a faster reduction in blood alcohol concentration (BAC) and alleviating symptoms of intoxication and hangover.
Quantum BioPharma’s shares jump 95%
The Toronto-based biopharmaceutical company conducted a double-blind, randomized, placebo-controlled crossover trial (NCT06505239), revealing that unbuzzd™ reduced BAC in study subjects an average of 40% faster within 30 minutes compared to a placebo. The trial’s findings showed statistically significant improvements in alertness, along with reductions in perceived impairment and hangover symptoms, with no adverse side effects reported.
Dr. Andrzej Chruscinski, Vice President of Clinical and Scientific Affairs at Quantum BioPharma, stated that the study produced “significant and meaningful outcomes.” He emphasized the absence of product-related side effects and the supplement’s potential to mitigate acute effects of alcohol intoxication.
CEO Zeeshan Saeed addressed the implications of unbuzzd™ for safer alcohol consumption, remarking on its ability to lessen intoxication, restore mental alertness, and help consumers avoid severe hangover symptoms. He noted, “This clinical trial shows that unbuzzd is an important addition to the safe and responsible consumption of alcohol.”
7% jump: Is Snap the social media stock to invest in 2025?
Business prospects and partnerships
Unbuzzd™, developed by Quantum BioPharma’s team, is licensed to Celly Nutrition Corp. and is available for purchase at unbuzzd.com. Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition and will receive 7% of sales royalties until a total of $250 million is paid, after which the royalty rate will drop to 3% in perpetuity.
In addition to unbuzzd™, Quantum BioPharma is developing treatments for neurodegenerative disorders, metabolic disorders, and alcohol misuse disorders, with its lead compound Lucid-MS targeting myelin degradation associated with multiple sclerosis.
Today’s stock movement reflects investor enthusiasm for the potential market impact of unbuzzd™ alongside Quantum BioPharma’s broader portfolio of health solutions. Quantum BioPharma is considered a low-float stock, with 1.83 million shares available for public trading and a market cap of approximately $6 million as of Monday’s close, contributing to the volatility seen in the stock’s surge.
A breakthrough product like unbuzzd™ that reduces blood alcohol concentration quickly can generate ongoing investor enthusiasm, especially in a market that thrives on innovative health solutions. If retail investors jump in, momentum could continue. With only 1.83 million publicly available shares, QNTM is highly susceptible to large price swings. Low-float stocks often experience multi-day rallies, but they can also reverse just as quickly. If the company announces distribution deals, regulatory approvals, or more clinical advancements, the stock could sustain its momentum.
After such a sharp gain, early investors may cash out too, leading to a potential pullback. Also, companies in this position often issue more shares to raise capital, which could dilute current shareholders. A positive trial is one thing; successfully marketing and selling unbuzzd™ at scale is another. If sales don’t meet expectations, the stock could lose steam. The massive gain could be fueled by short-term traders rather than long-term investors. If they exit quickly, the price could drop just as fast.
Disclaimer: The content of this article is for informational purposes only and should not be construed as investment advice. We do not endorse any specific investment strategies or make recommendations regarding the purchase or sale of any securities.
